Genomic Health Announces New Data Reinforcing Clinical Utility Of Oncotype DX(R) In M

[News]

Genomic Health, Inc. (Nasdaq: GHDX) announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer...

More... (http://www.medicalnewstoday.com/articles/174105.php)